VRDN

Viridian Therapeutics Inc

25.30

Nov 03 • 5:41 AM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: IMVT YARW ARGX DNTH ZBIO ANAB CLYM AUPH MLTX TRVI

| Held by: VTI XBI IWM VXF IWN DFAS SCHA VTWO DFAC IWC

Index	RUT
Market Cap	2.87B
Enterprise Value	2.23B
Income	-368.60M
Sales	71.13M
Book/sh	4.98
Cash/sh	8.66
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	252
IPO	Jun 18, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	40.30
P/B	5.08
P/C	2.92
P/FCF	-
EV/EBITDA	-
EV/Sales	31.29
Quick Ratio	16.95
Current Ratio	16.95
Debt/Eq	0.37
LT Debt/Eq	0.37
Option/Short	Yes / Yes

EPS (ttm)	-3.71
EPS next Y	-2.55
EPS next Q	-1.02
EPS this Y	-18.28%
EPS next Y	35.00%
EPS next 5Y	57.67%
EPS past 3/5Y	6.35% 36.07%
Sales past 3/5Y	241.95% 132.18%
EPS Y/Y TTM	13.06%
Sales Y/Y TTM	23220.33%
EPS Q/Q	4.56%
Sales Q/Q	278.67%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	-1.48% 403.55%

Insider Own	6.12%
Insider Trans	20.14%
Inst Own	119.83%
Inst Trans	11.11%
ROA	-43.89%
ROE	-62.62%
ROIC	-40.76%
Gross Margin	98.78%
Oper. Margin	-569.68%
Profit Margin	-518.22%
SMA20	17.14%
SMA50	16.58%
SMA200	16.71%
Trades

Shs Outstand	113.24M
Shs Float	106.36M
Short Float	16.93%
Short Ratio	9.81
Short Interest	18.00M
52W High	34.29 -26.22%
52W Low	13.18 91.96%
Volatility	4.39% 4.83%
ATR (14)	0.96
RSI (14)	72.25
Beta	1.07
Rel Volume	0.00
Avg Volume	1.84M
Volume	13

Perf Week	5.02%
Perf Month	33.16%
Perf Quarter	20.08%
Perf Half Y	34.93%
Perf YTD	-18.70%
Perf Year	9.29%
Perf 3Y	66.56%
Perf 5Y	41.18%
Perf 10Y	-62.52%
Recom	1.00
Target Price	36.20
Prev Close	25.30
Price	25.30
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$36.20

Implied Upside

+43.1%

Analysts16incl. previous ratings

Rating Distribution14 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 29, 2026	Upgrade	WWells Fargo	Equal Weight → Overweight	$31	+22.5%
Dec 10, 2025	Reiterated	WWedbush	Outperform	$42 → $47	+85.8%
Dec 03, 2025	Initiated	WWilliam Blair	Outperform
Nov 24, 2025	Initiated	TTruist	Buy
Aug 25, 2025	Resumed	JJefferies	Buy	$44	+73.9%
Dec 19, 2024	Downgrade	WWells Fargo	Overweight → Equal Weight	$37 → $27	+6.7%
Nov 25, 2024	Initiated	TTD Cowen	Buy
Sep 11, 2024	Reiterated	NNeedham	Buy	$30 → $38	+50.2%
Jun 11, 2024	Initiated	WWolfe Research	Outperform	$29	+14.6%
Jun 06, 2024	Initiated	GGoldman	Buy	$23	-9.1%
May 09, 2024	Downgrade	LLadenburg Thalmann	Buy → Neutral
May 09, 2024	Downgrade	RB. Riley Securities	Buy → Neutral	$25 → $20	-20.9%
Jun 14, 2023	Resumed	CCredit Suisse	Outperform	$51	+101.6%
Jun 14, 2023	Initiated	BBTIG Research	Buy	$46	+81.8%
May 30, 2023	Initiated	RRBC Capital Mkts	Outperform	$44	+73.9%
Apr 17, 2023	Initiated	WWells Fargo	Overweight	$46	+81.8%
Mar 30, 2023	Initiated	SStifel	Buy	$49	+93.7%
Dec 19, 2022	Initiated	NNeedham	Buy	$45	+77.9%
Dec 19, 2022	Initiated	CCowen	Outperform	$45	+77.9%
Dec 16, 2022	Initiated	CCredit Suisse	Outperform	$51	+101.6%

Oct-27-26 03:08PM	Viridian's Q3 Loss Should Hold Near $1 A Share; Cash And VRDN-001 Progress Matter More (Earnings Whispers)
Oct-20-26 04:00PM	Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 (Business Wire) +7.84%
Sep-02-26 04:00PM	Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference (Business Wire)
Aug-06-26 07:01AM	Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results (Business Wire) +6.83%
Jun-30-26 07:33AM	Viridian may have edge over Amgen in eye drug showdown, analysts argue (BioPharma Dive)
08:09AM	Loading…
Jun-29-26 08:09AM	Comcast, Viridian Therapeutics jump premarket; Doximity slips (Investing.com)
Jun-26-26 06:57PM	VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval (Stocktwits)
06:00PM	Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease (Business Wire)
May-27-26 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-06-26 11:13PM	Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million (Business Wire) -6.51%
08:13AM	Viridian Therapeutics stock up 35% after Phase III TED data release (Clinical Trials Arena)
May-05-26 04:05PM	Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock (Business Wire) +33.36%
10:24AM	PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results (InvestorsHub)
08:05AM	Can This Small Rival Take On Amgen's Eye Disease Blockbuster? (Investor's Business Daily)
08:04AM	Viridian data lift prospects for thyroid eye disease drug (BioPharma Dive)
07:01AM	Loading…
07:01AM	Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease (Business Wire)
Apr-06-26 12:10PM	Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. (Barrons.com) -26.22%
09:03AM	Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints (Investor's Business Daily)
Mar-31-26 06:48AM	Viridian tumbles on positive data for key eye drug prospect (BioPharma Dive) +5.56%
Mar-30-26 12:32PM	Viridian Therapeutics shares fall over 30% after trial data disappoints (Proactive) -32.35%
11:37AM	Viridian Therapeutics stock sinks despite positive Phase III TED data (Clinical Trials Arena)
09:20AM	Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results (Investor's Business Daily)
07:01AM	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL1 Clinical Trial in Active Thyroid Eye Disease (Business Wire)
Mar-06-26 10:20AM	RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating (Insider Monkey)
Feb-26-26 09:55AM	Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:01AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-25-26 07:25PM	MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-26 07:01AM	Viridian Therapeutics Prepares for Transformational 2026 (Business Wire)
07:00AM	Loading…
Dec-22-25 07:00AM	Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease (Business Wire)
Dec-15-25 04:34PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-16-25 10:14PM	RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results (Insider Monkey)
Nov-07-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-05-25 08:20AM	Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.29%
07:01AM	Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 07:01AM	Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease (Business Wire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-28-25 03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
Oct-21-25 11:24PM	Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock (Business Wire) -8.83%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering (Business Wire)
06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-20-25 07:30AM	Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million (Business Wire)
Oct-02-25 04:00PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-15-25 07:01AM	Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates (Business Wire)
Sep-03-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-17-25 11:41PM	Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront (Insider Monkey)
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-31-25 05:37AM	Viridian and Kissei to advance veligrotug and VRDN-003 in Japan (Pharmaceutical Technology)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive) +6.02%
04:00AM	Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments (Business Wire)
Jul-15-25 08:58AM	Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial (Insider Monkey) -5.13%
Jul-03-25 07:00AM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-25 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 07:00AM	Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) (Business Wire) +7.80%
May-07-25 04:15PM	Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) (Business Wire)
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.31%
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results (Business Wire)
May-02-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-07-25 07:00AM	Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-10-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-08-25 07:00AM	Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire) -8.42%
Dec-17-24 07:40AM	Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints (TipRanks)
Dec-16-24 04:09PM	Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen (Investor's Business Daily) +20.67%
09:28AM	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease (Investor's Business Daily)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease (Business Wire)
Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tousignant Jennifer	Chief Legal Officer	Aug 19 '26	Option Exercise	14.41	10,000	144,100	10,000	Aug 20 08:05 PM
Tousignant Jennifer	Chief Legal Officer	Aug 19 '26	Sale	24.50	14,212	348,194	0	Aug 20 08:05 PM
Tousignant Jennifer	Officer	Aug 19 '26	Proposed Sale	24.50	14,212	348,194		Aug 19 02:30 PM
Tripuraneni Radhika	Chief Medical Officer	Aug 14 '26	Option Exercise	13.21	40,000	528,400	40,000	Aug 18 05:34 PM
Fairmount Funds Management LLC	Director	May 11 '26	Buy	17.00	1,176,470	19,999,990	5,090,928	May 13 04:31 PM
Beetham Thomas W.	Officer	Mar 04 '26	Proposed Sale	30.19	3,048	92,004		Mar 04 04:29 PM
Tousignant Jennifer	Officer	Mar 04 '26	Proposed Sale	30.19	1,675	50,560		Mar 04 04:25 PM
Harmon Seth	Officer	Mar 04 '26	Proposed Sale	30.19	2,031	61,306		Mar 04 04:20 PM
Mahoney Stephen F.	Officer	Mar 04 '26	Proposed Sale	30.19	7,408	223,610		Mar 04 04:10 PM
Tousignant Jennifer	Chief Legal Officer	Dec 31 '25	Sale	31.16	2,272	70,796	0	Jan 02 05:25 PM
Tousignant Jennifer	Officer	Dec 31 '25	Proposed Sale	31.16	2,272	70,796		Dec 31 12:24 PM

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves' disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

MBAMr. Stephen F. Mahoney J.D.

Chief Financial OfficerMr. Seth Harmon

MBAMr. Thomas W. Beetham J.D.

Chief Legal Officer & Corporate SecretaryMs. Jennifer Tousignant J.D.

M.P.H.Dr. Radhika Tripuraneni M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRDN

Viridian Therapeutics Inc

Upgrade your Finviz experience